View in EDS HTML Full Text PDF Full Text

Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.
Authors: Sáez-Llorens X; Cevaxin, The Panama Clinic, Panama City, Panama.; Department of Infectious Diseases, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama.; Sistema Nacional de Investigación (SNI), National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama., deAntonio R; Cevaxin, The Panama Clinic, Panama City, Panama., López-Medina E; Centro de Estudios en Infectología Pediátrica S.A.S, Cali, Valle del Cauca, Colombia., López P; Centro de Estudios en Infectología Pediátrica S.A.S, Cali, Valle del Cauca, Colombia., Masuda T; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland., Mendelman PM; Clinical Development, Takeda Vaccines Inc, Cambridge, MA, USA., Sherwood J; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.; Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland., Baehner F; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland., Borkowski A; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.; Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2450878. Date of Electronic Publication: 2025 Jan 13.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39803784
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sáez-Llorens+X%22">Sáez-Llorens X</searchLink>; Cevaxin, The Panama Clinic, Panama City, Panama.; Department of Infectious Diseases, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama.; Sistema Nacional de Investigación (SNI), National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama.<br /><searchLink fieldCode="AU" term="%22deAntonio+R%22">deAntonio R</searchLink>; Cevaxin, The Panama Clinic, Panama City, Panama.<br /><searchLink fieldCode="AU" term="%22López-Medina+E%22">López-Medina E</searchLink>; Centro de Estudios en Infectología Pediátrica S.A.S, Cali, Valle del Cauca, Colombia.<br /><searchLink fieldCode="AU" term="%22López+P%22">López P</searchLink>; Centro de Estudios en Infectología Pediátrica S.A.S, Cali, Valle del Cauca, Colombia.<br /><searchLink fieldCode="AU" term="%22Masuda+T%22">Masuda T</searchLink>; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Mendelman+PM%22">Mendelman PM</searchLink>; Clinical Development, Takeda Vaccines Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sherwood+J%22">Sherwood J</searchLink>; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.; Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Baehner+F%22">Baehner F</searchLink>; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Borkowski+A%22">Borkowski A</searchLink>; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland.; Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2450878. <i>Date of Electronic Publication: </i>2025 Jan 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39803784
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21645515.2025.2450878
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2450878
    Titles:
      – TitleFull: Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sáez-Llorens X
      – PersonEntity:
          Name:
            NameFull: deAntonio R
      – PersonEntity:
          Name:
            NameFull: López-Medina E
      – PersonEntity:
          Name:
            NameFull: López P
      – PersonEntity:
          Name:
            NameFull: Masuda T
      – PersonEntity:
          Name:
            NameFull: Mendelman PM
      – PersonEntity:
          Name:
            NameFull: Sherwood J
      – PersonEntity:
          Name:
            NameFull: Baehner F
      – PersonEntity:
          Name:
            NameFull: Borkowski A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2164-554X
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Human vaccines & immunotherapeutics
              Type: main
ResultId 1